Boxer Capital LLC is a venture capital firm founded in 2005 and based in San Diego, California. As a subsidiary of Tavistock Life Sciences, it specializes in investing in both private and public companies within the biotechnology and life science sectors. Boxer Capital focuses on a wide range of companies involved in the drug development lifecycle, from early stage preclinical discovery assets to late stage clinical and commercial entities. The firm aims to support the growth and advancement of biotechnology innovations through its strategic investments.
Halda Therapeutics is a research-stage drug discovery company focused on developing next-generation precision medicines. The company utilizes a novel therapeutic modality aimed at creating treatments that can address various disease states. By modifying disease-causing pathways, Halda Therapeutics seeks to enable healthcare providers to offer tailored therapies to patients, enhancing the effectiveness of treatment based on individual patient needs.
Ajax Therapeutics
Series C in 2024
Ajax Therapeutics is a biotechnology company based in New York City that focuses on developing innovative small molecule therapies for hematologic malignancies. The company utilizes computational chemistry and structure-based technologies to create targeted treatments that address critical cytokine signaling pathways involved in these diseases. By integrating insights from disease mechanisms, genetics, and structural biology with an advanced computational drug discovery platform, Ajax Therapeutics aims to design precise therapeutics that meet significant unmet medical needs for patients suffering from hematologic malignancies.
iTeos Therapeutics
Post in 2024
iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.
Cullinan Therapeutics
Post in 2024
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.
Asher Bio
Series C in 2024
Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.
Eliem Therapeutics
Post in 2024
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that specializes in developing therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating innovative treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact millions of individuals. Eliem utilizes its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, including its lead candidate, ETX-155, aimed at addressing major depressive disorder and focal onset seizures. The company's mission centers on meeting unmet medical needs and improving patients' quality of life through its novel therapies.
Century Therapeutics
Post in 2024
Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.
ARTARA THERAPEUTICS
Post in 2024
ARTARA THERAPEUTICS is a clinical-stage healthcare company focused on developing transformative therapies for individuals with rare and specialty diseases. Its lead program, TARA-002, is an investigational cell therapy designed to treat lymphatic malformations and non-muscle invasive bladder cancer. Additionally, the company is advancing intravenous choline chloride, an investigational phospholipid substrate replacement therapy aimed at addressing intestinal failure-associated liver disease. Based in New York, ARTARA THERAPEUTICS is dedicated to providing innovative solutions for patients with limited treatment options, leveraging a team that values creativity and diverse perspectives to expedite the development of its therapies.
Alterome Therapeutics
Series B in 2024
Alterome Therapeutics is a biotechnology company focused on precision oncology, dedicated to developing targeted therapeutics that specifically address validated oncogenic drivers in cancer. The firm aims to discover and create alteration-specific therapies that provide hope and improved treatment options for individuals affected by cancer. By concentrating on high-value oncogenic alterations, Alterome Therapeutics seeks to enhance the effectiveness of cancer treatments and support healthcare providers in their efforts to combat the disease.
Nkarta Therapeutics
Post in 2024
Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cells for the treatment of cancer and autoimmune diseases. The company aims to enhance the efficacy of cell therapy by leveraging the inherent ability of NK cells to identify and eliminate abnormal cells without the need for genetic alteration. This approach allows for a broader application across various hematologic and solid tumor malignancies while potentially minimizing side effects associated with traditional T-cell therapies. Nkarta combines its NK expansion platform technology with proprietary cell engineering methods to produce a substantial supply of NK cells, enhancing their ability to recognize therapeutic targets and improving their persistence in the body for sustained activity. Through this innovative strategy, Nkarta seeks to provide more potent, well-tolerated, and rapidly available therapies for patients facing diverse cancer types.
Fate Therapeutics
Post in 2024
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.
Geron
Post in 2024
Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.
Spyre Therapeutics
Post in 2024
Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.
Avidity Biosciences
Post in 2024
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.
Jasper Therapeutics
Post in 2024
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.
Tyra Biosciences
Post in 2024
Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, that specializes in developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in cancer therapies through its proprietary SNÅP platform, which facilitates rapid and precise drug design by generating iterative molecular snapshots. Tyra is particularly focused on creating selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family, which are implicated in approximately 7% of all cancers. The company's lead product candidate, TYRA-300, specifically targets FGFR3 and is initially aimed at patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through its innovative approach, Tyra Biosciences seeks to improve treatment outcomes for cancer patients by providing alternatives to existing therapies.
Seismic Therapeutic
Series B in 2023
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.
Arvinas
Post in 2023
Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.
ORIC Pharmaceuticals
Post in 2023
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.
Abivax
Post in 2023
Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.
Alterome Therapeutics
Series A in 2022
Alterome Therapeutics is a biotechnology company focused on precision oncology, dedicated to developing targeted therapeutics that specifically address validated oncogenic drivers in cancer. The firm aims to discover and create alteration-specific therapies that provide hope and improved treatment options for individuals affected by cancer. By concentrating on high-value oncogenic alterations, Alterome Therapeutics seeks to enhance the effectiveness of cancer treatments and support healthcare providers in their efforts to combat the disease.
SpringWorks Therapeutics
Post in 2022
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.
Gossamer Bio
Post in 2022
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.
Incyclix Bio
Series B in 2022
Incyclix Bio is a biotechnology company based in Durham, North Carolina, focused on the development of small molecule inhibitors targeting cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. Founded in 2020 by a team including Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman, the company aims to provide potent and selective inhibition of challenging CDK targets. This approach enables pharmaceutical companies and medical practitioners to access innovative therapeutic options, thereby enhancing treatment opportunities for cancer patients facing difficult cases. Through its research and development efforts, Incyclix Bio seeks to contribute to the advancement of cancer treatment solutions.
Seismic Therapeutic
Series A in 2022
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.
Alterome Therapeutics
Series A in 2022
Alterome Therapeutics is a biotechnology company focused on precision oncology, dedicated to developing targeted therapeutics that specifically address validated oncogenic drivers in cancer. The firm aims to discover and create alteration-specific therapies that provide hope and improved treatment options for individuals affected by cancer. By concentrating on high-value oncogenic alterations, Alterome Therapeutics seeks to enhance the effectiveness of cancer treatments and support healthcare providers in their efforts to combat the disease.
Ceptur Therapeutics
Series A in 2022
Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.
Enliven Therapeutics
Series B in 2022
Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.
Third Harmonic Bio
Series B in 2022
Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergies and inflammation. The company is focused on creating first-in-class oral small-molecule inhibitors targeting the KIT receptor, which plays a crucial role in the survival and function of mast cells—key immune cells involved in allergic responses. Its lead product candidate, THB001, is designed to provide selective inhibition of KIT, while another candidate, THB335, aims to address multiple mast cell-driven inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to advance the management of inflammatory diseases, enhancing patient outcomes and quality of life.
Asher Bio
Series B in 2021
Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.
Point Biopharma Global
Post in 2021
POINT Biopharma Global Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of radioligand therapies for cancer treatment. The company is focused on creating a robust platform for the clinical development of radiopharmaceuticals, utilizing advanced radioisotopes such as Actinium-225 and Lutetium-177. POINT Biopharma's product pipeline includes several candidates, such as PNT2002, PNT2004, PNT2003, and PNT2001, among others. By leveraging a combination of innovative manufacturing technology and direct-to-patient targeting, POINT Biopharma aims to transform theragnostic drug development and enhance the commercialization of radioligands in the fight against cancer.
Ajax Therapeutics
Venture Round in 2021
Ajax Therapeutics is a biotechnology company based in New York City that focuses on developing innovative small molecule therapies for hematologic malignancies. The company utilizes computational chemistry and structure-based technologies to create targeted treatments that address critical cytokine signaling pathways involved in these diseases. By integrating insights from disease mechanisms, genetics, and structural biology with an advanced computational drug discovery platform, Ajax Therapeutics aims to design precise therapeutics that meet significant unmet medical needs for patients suffering from hematologic malignancies.
Flare Therapeutics
Series A in 2021
Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company aims to identify 'switch sites,' which are druggable regions crucial for regulating transcription factors, to target mutations associated with various diseases. Flare's innovative approach has advanced its drug discovery efforts, resulting in a promising pipeline of programs that primarily address well-established transcription factors. Initially concentrating on precision oncology, the company's research also holds potential applications in neurology, rare genetic disorders, immunology, and inflammation. By leveraging insights from its scientific founders, Flare Therapeutics seeks to transform the treatment landscape for cancer patients and other disease areas.
Nuvalent
Series B in 2021
Nuvalent is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, specifically aimed at clinically validated kinase targets. With a strong foundation in structure-based design, Nuvalent creates small molecules that exhibit high selectivity, aiming to address issues of resistance and minimize side effects associated with conventional treatments. The company's pipeline includes lead programs such as NVL-520 for ROS1-positive non-small cell lung cancer (NSCLC) and NVL-655 for ALK-positive NSCLC, as well as several discovery-stage initiatives. All operations are conducted within the United States, where Nuvalent seeks to enhance treatment options for patients with significant unmet medical needs.
Theseus Pharmaceuticals
Series B in 2021
Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients by discovering, developing, and commercializing innovative targeted therapies. The company's primary focus is on addressing drug resistance mutations in key driver oncogenes, which are mutated genes that contribute to the progression of cancer. By leveraging advanced technologies, Theseus Pharmaceuticals aims to create transformative treatments that can overcome challenges associated with existing therapies, thereby improving patient outcomes in oncology.
GH Research
Series B in 2021
GH Research PLC is a clinical-stage biopharmaceutical company that aims to transform the treatment of psychiatric and neurological disorders. The company is primarily focused on developing novel and proprietary therapies based on 5-MeO-DMT, a compound known as Mebufotenin, to address the needs of patients suffering from Treatment-Resistant Depression (TRD). Through its innovative approach, GH Research seeks to provide new therapeutic options for individuals who have not responded to conventional treatments.
Tyra Biosciences
Series B in 2021
Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, that specializes in developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in cancer therapies through its proprietary SNÅP platform, which facilitates rapid and precise drug design by generating iterative molecular snapshots. Tyra is particularly focused on creating selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family, which are implicated in approximately 7% of all cancers. The company's lead product candidate, TYRA-300, specifically targets FGFR3 and is initially aimed at patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through its innovative approach, Tyra Biosciences seeks to improve treatment outcomes for cancer patients by providing alternatives to existing therapies.
Asher Bio
Series A in 2021
Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.
Day One Biopharmaceuticals
Series B in 2021
Day One Biopharmaceuticals is a clinical-stage biotechnology company that specializes in developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric patients. Recognizing the advancements in cancer research, the company aims to create treatments that can benefit both children and adults diagnosed with genetically defined cancers. Day One Biopharmaceuticals prioritizes the rapid development of therapies to meet the urgent needs of families facing cancer diagnoses. Their lead product candidate, DAY101, is an oral, highly-selective pan-RAF kinase inhibitor designed to penetrate the brain, addressing a significant treatment gap in pediatric oncology. By licensing and acquiring promising products from research institutions and other companies, Day One Biopharmaceuticals strives to bring effective medicines to market for those impacted by cancer.
Gemini Therapeutics
Post in 2021
Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.
Shoreline Biosciences
Venture Round in 2021
Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.
Biomea Fusion
Series A in 2021
Biomea Fusion is a preclinical-stage biopharmaceutical company dedicated to advancing precision medicine for cancer treatment. The company's focus is on the discovery and development of irreversible small molecule drugs that target specific genetic alterations associated with tumor growth. Its lead product candidate, BMF-219, is designed as a potent and selective irreversible inhibitor of menin, a key transcriptional regulator involved in oncogenic signaling across various cancers. Biomea Fusion aims to expedite the development of these innovative therapies to provide highly effective treatment options for patients with genetically defined cancers.
Vivace Therapeutics
Series C in 2020
Vivace Therapeutics, Inc. is a drug discovery and development company focused on creating cancer therapies that target the Hippo pathway, which plays a crucial role in tissue regeneration and organ development. Established in 2014 and located in the San Francisco Bay Area, Vivace Therapeutics employs an innovative approach to develop small molecule treatments aimed at improving patient outcomes in oncology. The company collaborates with leading academic institutions to advance research and develop therapies that can be used alone or in combination with existing treatments. With a commitment to enhancing cancer care, Vivace Therapeutics is dedicated to delivering novel solutions that can help patients combat cancer more effectively.
Solid Biosciences
Post in 2020
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Achilles Therapeutics
Series C in 2020
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.
Elevation Oncology
Series B in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.
Cedilla Therapeutics
Series B in 2020
Cedilla Therapeutics, Inc. is focused on developing targeted small-molecule medicines aimed at treating cancer and other diseases resulting from protein dysregulation. The company leverages unique insights into protein stability to create innovative therapeutic approaches, including direct ligand-induced degradation, disruption of protein-protein interactions, and the identification of upstream regulators that influence protein stability. Cedilla’s technology allows for the mapping of protein susceptibility to enhance endogenous degradation pathways, facilitating the transition from stable to susceptible protein states. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cedilla Therapeutics aims to broaden the applicability of its therapies beyond oncology, addressing a range of conditions associated with protein dysregulation.
Silverback Therapeutics
Series C in 2020
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.
Rain Oncology
Series B in 2020
Rain Oncology Inc. is a late-stage precision oncology company focused on developing therapies that target oncogenic drivers. The company employs a tumor-agnostic approach, selecting patients based on the underlying genetics of their tumors rather than their histological characteristics. Its leading product candidate, milademetan, is an oral small molecule inhibitor of MDM2, which plays a role in various cancers. In addition to milademetan, Rain Oncology is advancing a preclinical program aimed at inducing synthetic lethality in cancer cells through the inhibition of RAD52. This targeted strategy aims to improve treatment outcomes for patients who are genetically predisposed to benefit from these therapies.
Tango Therapeutics
Venture Round in 2020
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies through the principle of synthetic lethality. Established in 2014, the company aims to discover and target specific driver genes involved in cancer progression. Its research concentrates on three main areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that outperform single-agent therapies. Tango's pipeline includes TNG908, a selective inhibitor of PRMT5 designed for cancer cells with an MTAP deletion, alongside other discovery programs like TNG462, TNG348, and TNG260, which target various cancer types with limited treatment options.
PMV Pharmaceuticals
Series D in 2020
PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.
BioAtla
Series D in 2020
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.
Fulcrum Therapeutics
Post in 2020
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.
Mereo Biopharma
Post in 2020
Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.
Tango Therapeutics
Series B in 2020
Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies through the principle of synthetic lethality. Established in 2014, the company aims to discover and target specific driver genes involved in cancer progression. Its research concentrates on three main areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that outperform single-agent therapies. Tango's pipeline includes TNG908, a selective inhibitor of PRMT5 designed for cancer cells with an MTAP deletion, alongside other discovery programs like TNG462, TNG348, and TNG260, which target various cancer types with limited treatment options.
Pandion Therapeutics
Series B in 2020
Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.
Nurix Therapeutics
Venture Round in 2020
Nurix Therapeutics is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule therapies aimed at modulating cellular protein levels to treat cancer and immune disorders. The company's pipeline includes promising preclinical candidates such as NX-2127, an orally available Bruton’s tyrosine kinase degrader targeted at relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology applications. Nurix's innovative drug discovery platform, DELigase, leverages its expertise in E3 ligases—enzymes that regulate protein modulation within cells—to identify and advance novel drug candidates. Founded in 2009 and based in San Francisco, Nurix Therapeutics aims to provide effective therapies for challenging diseases through its cutting-edge research and development efforts.
Syndax Pharmaceuticals
Post in 2020
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.
Aligos Therapeutics
Series B in 2020
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.
Tyra Biosciences
Series A in 2020
Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, that specializes in developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in cancer therapies through its proprietary SNÅP platform, which facilitates rapid and precise drug design by generating iterative molecular snapshots. Tyra is particularly focused on creating selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family, which are implicated in approximately 7% of all cancers. The company's lead product candidate, TYRA-300, specifically targets FGFR3 and is initially aimed at patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through its innovative approach, Tyra Biosciences seeks to improve treatment outcomes for cancer patients by providing alternatives to existing therapies.
Black Diamond Therapeutics
Series C in 2019
Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.
PMV Pharmaceuticals
Series C in 2019
PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.
Boundless Bio
Series A in 2019
Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.
Passage Bio
Series B in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Solid Biosciences
Post in 2019
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Revolution Medicines
Series C in 2019
Revolution Medicines is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for cancer treatment. Founded by Martin D. Burke, the company leverages an innovative approach to synthesize complex natural products into optimized drug candidates. This method involves rapidly assembling simple chemical building blocks into refined structures with significant therapeutic potential. Revolution Medicines focuses on inhibiting elusive targets within key growth and survival pathways, particularly RAS and mTOR signaling pathways. The company's portfolio includes therapies like RMC-4630, a SHP2 inhibitor, as well as programs targeting SOS1 and 4EBP1/mTORC1.
Encoded Therapeutics
Series C in 2019
Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.
Poseida Therapeutics
Series C in 2019
Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.
SpringWorks Therapeutics
Series B in 2019
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.
Prevail Therapeutics
Series B in 2019
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.
Attune Pharmaceuticals
Series B in 2019
Attune Pharmaceuticals, Inc. is a biotechnology research and development company based in New York, established in 2015. The company specializes in discovering and developing novel orally administered small molecule therapeutics aimed at treating rare diseases. Its focus includes the creation of heterocyclic derivative compounds and pharmaceutical compositions that address conditions such as hereditary angioedema, thereby providing clinicians with effective treatment options for rare medical conditions.
Sojournix
Series C in 2019
Sojournix, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative therapies for women's health and neuroendocrine disorders. Founded in 2016, the company is advancing SJX-653, a selective neurokinin-3 antagonist designed as a non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause. By aiming to provide safe and effective alternatives to current treatment options, Sojournix seeks to improve healthcare outcomes for women suffering from these conditions.
Cabaletta Bio
Series B in 2019
Cabaletta Bio is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, specializing in the discovery and development of engineered T cell therapies aimed at treating B cell-mediated autoimmune diseases. The company's proprietary technology employs chimeric autoantibody receptor (CAAR) T cells that selectively target and eliminate pathogenic B cells responsible for producing harmful autoantibodies, while preserving healthy B cells that are vital to immune function. The lead product candidate, DSG3-CAART, is currently undergoing Phase I clinical trials for the treatment of mucosal pemphigus vulgaris, a rare autoimmune skin disorder, and Hemophilia A with Factor VIII alloantibodies. Additionally, Cabaletta has a pipeline that includes MuSK-CAART for myasthenia gravis and FVIII-CAART for Hemophilia A, both at various stages of development. The company has established collaborations with the University of Pennsylvania and research agreements with the University of California, enhancing its research and development efforts. Founded in 2017, Cabaletta Bio was previously known as Tycho Therapeutics, Inc. before rebranding in 2018.
Akero Therapeutics
Series B in 2018
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.
Milestone Pharmaceuticals
Series D in 2018
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.
Atreca
Series C in 2018
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.
CiVi Biopharma
Venture Round in 2018
CiVi Biopharma is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and metabolic diseases, particularly those with significant unmet medical needs. The company is advancing multiple assets in its pipeline, including Intravenous Iloprost, which is currently undergoing Phase 3 trials for the treatment of Systemic Sclerosis. By concentrating on both cardiovascular and rare diseases, CiVi Biopharma aims to provide valuable therapeutic options that enhance patient care and improve health outcomes.
MEI Pharma
Post in 2018
MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.
IDEAYA Biosciences
Series B in 2018
IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.
Prevail Therapeutics
Series A in 2018
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.
Codiak Biosciences
Series C in 2017
Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.
GTx
Post in 2017
GTx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specializes in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders, targeting conditions such as breast cancer and Duchenne muscular dystrophy. One of its notable product candidates is enobosarm GTx-024, which is undergoing Phase II clinical trials for patients with specific types of breast cancer and postmenopausal women suffering from stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aims to advance medical solutions by leveraging new scientific approaches. In 2019, GTx was acquired by Oncternal Therapeutics in a reverse merger.
CiVi Biopharma
Series A in 2017
CiVi Biopharma is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular and metabolic diseases, particularly those with significant unmet medical needs. The company is advancing multiple assets in its pipeline, including Intravenous Iloprost, which is currently undergoing Phase 3 trials for the treatment of Systemic Sclerosis. By concentrating on both cardiovascular and rare diseases, CiVi Biopharma aims to provide valuable therapeutic options that enhance patient care and improve health outcomes.
Telesta Therapeutics
Venture Round in 2015
Telesta Therapeutics is a Canadian biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative therapeutics aimed at addressing significant unmet medical needs, primarily in oncology. The company is focused on creating novel medicines that can transform the treatment landscape for serious diseases, including cancer and immune disorders. Its lead product, MCNA, has successfully completed a Phase III pivotal study for patients with non-muscle invasive bladder cancer who have not responded to initial treatment with bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application to the U.S. FDA in June 2015 and aims to provide MCNA to patients and healthcare providers pending approval. Ultimately, the company seeks to enhance the quality of life and extend survival for individuals affected by bladder cancer, one of the most prevalent cancers today.
Nabriva Therapeutics
Series B in 2015
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.
G1 Therapeutics
Series B in 2015
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.